Dr. May Orfali M.B.A., M.D. Net Worth

Dr. May Orfali M.B.A., M.D. biography

Dr. May Orfali M.B.A., M.D. is the Exec. VP & Chief Medical Officer at Sigilon Therapeutics.

What is the salary of Dr D?

As the Exec. VP & Chief Medical Officer of Sigilon Therapeutics, the total compensation of Dr D at Sigilon Therapeutics is $536,673. There are 1 executives at Sigilon Therapeutics getting paid more, with Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA having the highest compensation of $802,372.

How old is Dr D?

Dr D is 53, he's been the Exec. VP & Chief Medical Officer of Sigilon Therapeutics since . There are 4 older and 2 younger executives at Sigilon Therapeutics. The oldest executive at Sigilon Therapeutics, Inc. is Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD, 72, who is the Co-Founder & Member of Scientific Advisory Board.

What's Dr D's mailing address?

May's mailing address filed with the SEC is C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET STE 600, CAMBRIDGE, MA, 02142.

Insiders trading at Sigilon Therapeutics

Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui..., and John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.

What does Sigilon Therapeutics do?

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sigilon Therapeutics executives and stock owners

Sigilon Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA,
  Pres, CEO & Director
• Dr. May Orfali M.B.A., M.D.,
  Exec. VP & Chief Medical Officer
• Philip Ashton-Rickardt Ph.D.,
  Chief Scientific Officer
• Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Daniel G. Anderson Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. José Oberholzer M.D.,
  Co-Founder
• Matthew Kowalsky J.D.,
  Chief Legal Officer
• Robert Windsor Jr., J.D.,
  VP & Head of Investor Relations
• Josias Fantato De Pontes M.B.A.,
  Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer
• Dr. Arturo Vegas Ph.D.,
  Co-Founder
• Dr. José Oberholzer M.D.,
  Co-Founder
• Dr. Omid Veiseh Ph.D.,
  Co-Founder
• Coelho Rogerio Vivaldi,
  PRESIDENT AND CEO
• Glenn Reicin,
  CHIEF FINANCIAL OFFICER
• Deya Corzo,
  CHIEF MEDICAL OFFICER
• Devyn Smith,
  CHIEF OPERATING OFFICER
• Lilly & Co Shenandoah Acqui...,
  
• Douglas G. Cole,
  
• Kavita Patel,
  
• Stephen N. Oesterle,
  
• Eric D. Shaff,
  
• Ventures Fund V General Par...,
  
• John Cox,
  
• Lilly & Co Eli,
  10% owner
• Robert R Ruffolo,
  
• Brooke Story,
  
• Philip Ashton Rickardt,
  CHIEF SCIENTIFIC OFFICER
• Daniel Griffith Anderson,
  
• Qing Sarah Yuan,
  CTOO
• May Orfali,
  CHIEF MEDICAL OFFICER
• Matthew Paul Kowalsky,
  CHIEF OF STAFF AND CLO
• Josias Pontes,
  CHIEF FINANCIAL OFFICER